Simon S. Jones

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.